CX-8998

DRUG3 trials

Sponsors

Jazz Pharmaceuticals

Conditions

EpilepsyEssential TremorParkinson's DiseaseTremor

Phase 2

A Phase 2 RCT Study of CX-8998 for Essential Tremor

CompletedNCT03101241

Jazz PharmaceuticalsEssential Tremor

Start: 2017-08-29End: 2018-07-16Updated: 2021-11-23

CX-8998 for Absence Seizures

CompletedNCT03406702

Jazz PharmaceuticalsEpilepsy

Start: 2018-02-25End: 2019-03-29Updated: 2022-09-08

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

WithdrawnNCT03436953

Jazz PharmaceuticalsParkinson's Disease, Tremor

Start: 2019-12-31End: 2020-12-31Updated: 2021-05-28

Related Papers

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection

Frontiers in Neurology2019-06-1122 citations